(Q82976088)
Statements
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy (English)
Ken Wyman
Michael B Atkins
Victor Prieto
David F McDermott
Francie Hubbard
Christine Byrnes
Kathleen Sanders
Jeffrey A Sosman